European Leukemia Trial Registry
Trial: CML IV

More Details
Title Imatinib vs. Imatinib+Interferon or Imatinib 800mg and SCT in CML
Scientific Title Phase IV Randomized Controlled Study of Standard-Dose Imatinib Mesylate (400 mg) Alone or with Interferon alfa Versus High-dose Imatinib Mesylate (800 mg) and Determination of the Role of Allogeneic Stem Cell Transplantation in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Short Title CML IV
Trialgroup CML-Studiengruppe
Type of Trial multicentric, randomized
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age All ages
Status No longer recruiting
Start of Recruitment 01.03.2002
Leader Hehlmann, Prof. Dr. med., Rüdiger
Contactperson

Study Physician
Hochhaus, Prof. Dr. med., Andreas
Tel: +49 (0)3641 932 4201
Fax: +49 (0)3641 932 4202
Email: andreas.hochhaus@med.uni-jena.de

Biometrics
Hasford, Prof. Dr. med., Jörg
Tel: +49 (0)89 57095 7481
Fax: +49 (0)89 57095 7482
Email: has@ibe.med.uni-muenchen.de
Homepage: http://www.ibe.med.uni-muenchen.de/

Biometrics
Pfirrmann, Dr., Markus
Tel: +49 (0)89 544201-40
Fax: +49 (0)89 544201-44
Email: pfi@ibe.uni-muenchen.de
Homepage: http://www.ibe.med.uni-muenchen.de/

Centre of Trial Medizinische Fakultät Mannheim der Universität Heidelberg
Shortprotocol Shortprotocol
Diagnostics

Molecular Genetics
Molekulargenetisches Labor der III Med.Klinik, Universitätsmedizin Mannheim

Morphology
Pathologisches Institut der Universität Hannover
Pathologisches Institut der Universität Köln

Cytogenetics
Institut für Humangenetik, Medizinische Hochschule Hannover (MHH)

Cytogenetics (with costs)
MLL Münchner Leukämielabor GmbH

created 06.06.2006 Anja Hellenbrecht
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org